News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Open Biosystems' Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina

3/11/2008 10:34:54 AM

HUNTSVILLE, Ala., March 11 /PRNewswire/ -- Open Biosystems, Inc. announced today that Harvard Medical School and the University of North Carolina have joined the Open Access(TM) RNAi Program. Each University purchased access to whole genome human and mouse lentiviral shRNA libraries developed by The RNAi Consortium and distributed by Open Biosystems.

(Logo: )

Tal Kafri M.D. Ph.D., Associate Professor in the Department of Microbiology and Immunology at the Gene Therapy Center, said, "Open Biosystems' Open Access Program empowers all researchers at the University of North Carolina with the ultimate promise of RNAi by offering unrestricted access to genome scale RNAi resources. From knockdown of single genes to pathway and whole genome RNAi screening with lentiviral shRNA, this program will definitely accelerate the pace of discovery at UNC."

"They are a welcome addition to the collaborative network of investigators worldwide implementing the latest advancements in shRNA technologies," said Troy Moore, Chief Technical Officer. "Participation in the Open Access Program enables investigators throughout these institutions to access their choice of Open Biosystems' unique portfolio of genome-wide RNAi resources."

Open Biosystems' portfolio of RNAi resources include shRNAmir lentiviral and retroviral libraries targeting the entire human and mouse genomes, The RNAi Consortium human and mouse lentiviral shRNA libraries and RNAi libraries targeting Drosophila, C. elegans and Arabidopsis thaliana. Participation in the Open Access RNAi program provides researchers the most complete and flexible access to their choice of these rapidly evolving RNAi technologies.

About Open Access RNAi

The Open Biosystems Open Access RNAi Program gives entire academic systems, including multiple campuses, access to the company's advanced RNAi libraries, priority technical support, and continued access to all extensions of existing libraries as well as library upgrades. In this manner, Open Biosystems supports academic research without imposing heavy financial burdens on individual labs. The program is customizable and can be tailored to fit the diverse needs of research institutions worldwide. Complete details can be found at

About Open Biosystems

Open Biosystems, Inc. develops, manufactures and markets genomic research tools to scientists and researchers in corporate, academic and government laboratories. These research tools provide investigators with standardized high-quality genes, RNAi and antibodies for interrogating gene function in relation to oncology, neuroscience and metabolic disorders. Founded in 2001, Open Biosystems is headquartered in Huntsville, Alabama. For more information and details for ordering, please visit

CONTACT: Dr. Gwen Fewell, Open Biosystems, Inc., +1-256-319-1489

Web site:

Read at

comments powered by Disqus